Diabetes News and Research

Latest Diabetes News and Research

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Blue Shield of California is now offering the Healthways SilverSneakers® Fitness Program to subscribers of Blue Shield Medicare Supplement Plans throughout California. SilverSneakers, the nation's leading social support and exercise program designed to keep seniors healthy, has been a popular benefit with California Medicare HMOs, but Blue Shield is one of the few health plans in the state to offer the benefit as part of its Medicare Supplement plans as well.

30 Jun 2010

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Experts from all over the world will be converging on the Park Plaza Hotel in Westminster, London, from 2 - 4 December 2010 for Excellence in Paediatrics, which promises cutting edge topics by outstanding speakers.

30 Jun 2010

Sensor integrated insulin pump for better blood sugar control

Adding a continuous blood sugar level sensor to an insulin pump helps patients with type 1 diabetes achieve better blood sugar control compared to the common standard of care, multiple daily insulin injections, concludes a study published on-line today in the New England Journal of Medicine.

30 Jun 2010

Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study

In the longest and largest randomized, controlled study of sensor-augmented insulin pump therapy in type 1 diabetes, adult and pediatric patients using the Medtronic MiniMed Paradigm® REAL-Time System achieved better glucose control without an increase in hypoglycemia compared to multiple daily insulin injections (MDI), the most common approach to care today.

30 Jun 2010

European Congress of Nephrology unveils results of various clinical trials

The 47th ERA-EDTA/DGfN congress in Munich has been the setting for a wide range of new clinical data. The results of the following clinical trials were presented at "Late-Breaking Clinical Trials Sessions."

30 Jun 2010

Striking disparities persist; obesity rates highest among Blacks and Latinos

Adult obesity rates increased in 28 states in the past year, and declined only in the District of Columbia, according to F as in Fat: How Obesity Threatens America's Future 2010, a report from the Trust for America's Health and the Robert Wood Johnson Foundation.

30 Jun 2010

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

In people with longstanding type 2 diabetes who are at high risk for heart attack and stroke, lowering blood sugar to near-normal levels did not delay the combined risk of diabetic damage to kidneys, eyes, or nerves, but did delay several other signs of diabetic damage, a study has found. The intensive glucose treatment was compared with standard glucose control.

30 Jun 2010

Study highlights importance of individualized, patient-centered therapies

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

30 Jun 2010

Physically-active women have lower risk of dementia in later life

Women who are physically active at any point over the life course (teenage, age 30, age 50, late life) have lower risk of cognitive impairment in late-life compared to those who are inactive, but teenage physical activity appears to be most important.

30 Jun 2010

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

Metabolex and Sanofi-Aventis announced today that they have entered into a global license and development agreement for the research, development, manufacture and commercialization of small molecules that modulate the G-protein coupled receptor 119 (GPR119), a receptor in the gut and pancreas that interacts with bioactive lipids to stimulate glucose-dependent incretin and insulin secretion.

30 Jun 2010

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

The Washington Post: Two new studies provide evidence "that the diabetes drug Avandia increases the risk of heart problems and strokes, renewing questions about the safety of the medication. ... The new research, released Monday, should prompt the Food and Drug Administration to remove the drug from the market, according to the researchers who led the analyses and several drug-safety advocates.

30 Jun 2010

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a study comparing the effect of long-term treatment with either BYETTA® (exenatide) injection or Lantus® (insulin glargine) on overall beta-cell function. (Beta cells are cells in the pancreas that produce insulin.) Three years of BYETTA therapy improved indices of beta-cell function assessed four weeks after discontinuing therapy. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) in Orlando, Fla.

30 Jun 2010

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

The U.S. Food & Drug Administration (FDA) has granted Investigational New Drug (IND) regulatory clearance to initiate a Phase I/II clinical trial evaluating Alpha-1 Antitrypsin (AAT) in type 1 diabetics, based on research by Dr. Eli Lewis of Israel's Ben-Gurion University of the Negev.

30 Jun 2010

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

In high-risk adults with type 2 diabetes, researchers have found that two therapies may slow the progression of diabetic retinopathy, an eye disease that is the leading cause of vision loss in working-age Americans.

30 Jun 2010

Importance of cell-cell communication in ischaemia

A team from the Bristol Heart Institute have investigated the importance of cell-cell communication in regulating the formation of new blood vessels following the restriction in blood supply to the heart or back leg in mice.

29 Jun 2010

Alimera submits Iluvien NDA for DME to FDA

Alimera Sciences, Inc.,, a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Iluvien®, (flucocinolone acetonide intravitreal insert), its investigational, sustained drug delivery system releasing sub-microgram levels of fluocinolone acetonide for the treatment of diabetic macular edema (DME).

29 Jun 2010

BBD reports analyze effectiveness and safety of statin use

A series of new reports from Consumer Reports Best Buy Drugs (BBD) caution that the benefits of statin use by children and some women may not outweigh the risks. Drugs to lower cholesterol - including statins - are the most commonly prescribed drugs in the U.S. and garnered more than $14 billion in sales last year.

29 Jun 2010

Individual cells react differently to complex signals: Study

Using new technology that allows scientists to monitor how individual cells react in the complex system of cell signaling, Stanford University researchers have uncovered a much larger spectrum of differences between each cell than ever seen before.

29 Jun 2010

Vitae earns $14M milestone payment from Boehringer Ingelheim

Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.

29 Jun 2010

First Edition: June 29, 2010

In this Kaiser Health News consumer column, Michelle Andrews writes: "Sarah Rose Nordgren works 25 to 30 hours a week as a waitress at an upscale restaurant in Chapel Hill, N.C. She also tutors high- schoolers on their college entrance essays and has an editorial internship at a book publisher. But if something were to go seriously wrong with her health, she'd be in trouble because none of her three jobs offers health insurance" (Kaiser Health News).

29 Jun 2010

Diabetes News and Research

Latest Diabetes News and Research

Blue Shield of California offers SilverSneakers Fitness Program to Medicare Supplement Plan subscribers

Excellence in Paediatrics to be held in London, from 2 - 4 December 2010

Sensor integrated insulin pump for better blood sugar control

Medtronic's sensor-augmented insulin pump therapy provides superior glucose control, confirms STAR 3 study

European Congress of Nephrology unveils results of various clinical trials

Striking disparities persist; obesity rates highest among Blacks and Latinos

Study: Near-normal glucose control does not delay risk of organ damage in diabetes patients

Study highlights importance of individualized, patient-centered therapies

Physically-active women have lower risk of dementia in later life

Metabolex, Sanofi-Aventis sign global license deal to develop GPR119 for type 2 diabetes treatment

2 new studies add to evidence of risks with diabetes drug Avandia as FDA prepares to debate it's safety

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

FDA grants IND regulatory clearance for Phase I/II clinical trial of AAT in type 1 diabetics

Study indicates two treatment strategies can reduce progression of diabetic retinopathy

Importance of cell-cell communication in ischaemia

Alimera submits Iluvien NDA for DME to FDA

BBD reports analyze effectiveness and safety of statin use

Individual cells react differently to complex signals: Study

Vitae earns $14M milestone payment from Boehringer Ingelheim

First Edition: June 29, 2010

Industry Focus eBook - Medical device (1st edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Diabetes News and Research

Latest Diabetes News and Research

Industry Focus eBook - Medical device (1st edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in